FDA approves Quill's tissue repair device:
This article was originally published in Clinica
The US FDA has approved for sale Quill Medical's barbed polydioxanone suture for closing wounds in dermal tissue. The product represents the first in a line of tissue repair devices being developed by the company, that enables sutures to "self-anchor" themselves in tissue without the surgeon having to perform a suture knot, said the Research Triangle Park, North Carolina-based firm. Quill Medical CE marked the product for sale in Europe in May.
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.